Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.
Ina ChenLesley Mathews-GreinerDandan LiAbisola Abisoye-OgunniyanSatyajit RayYansong BianVivek ShuklaXiaohu ZhangRaj GuhaCraig ThomasBerkley GryderAthina ZachariaJoal D BeaneSarangan RavichandranMarc FerrerUdo RudloffPublished in: Journal of translational medicine (2017)
Integrated pharmacological and transcriptomic profiling of hereditary diffuse gastric cancer cells with a loss-of-function c.1380delA CDH1 mutation implies various pharmacological vulnerabilities selective to CDH1-deficient familial gastric cancer cells and suggests novel treatment leads for future preclinical and clinical treatment studies of familial gastric cancer.